Edgewise Therapeutics (EWTX) Retained Earnings (2020 - 2026)
Edgewise Therapeutics (EWTX) posted Retained Earnings of -$595.4 million for Q1 2026, down 155.75% sequentially from $1.1 billion in Q4 2025, and down 170.16% YoY from $848.7 million in Q1 2025.
Edgewise Therapeutics (EWTX) Retained Earnings (2020 - 2026) Analysis & Trends
Edgewise Therapeutics has reported Retained Earnings for 7 years, with the latest figure at -$595.4 million in Q1 2026.
- Quarterly Retained Earnings fell 170.16% year-over-year to -$595.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$595.4 million (down 170.16% YoY) and the FY2025 annual result came in at $1.1 billion, up 254171.67% from the prior year.
- Retained Earnings eased to -$595.4 million in Q1 2026 per EWTX's latest filing, from $1.1 billion in the prior quarter.
- Over five years, Retained Earnings peaked at $1.1 billion in Q4 2025 and troughed at -$595.4 million in Q1 2026.
- A 5-year average of $108.7 million and a median of -$1.1 million in 2024 frame the typical range for Retained Earnings.
- The widest YoY moves for Retained Earnings: up 655475.93% in 2022, down 326224.24% in 2022.
- Over 5 years, Retained Earnings stood at -$1.4 million in 2022, then surged by 107.31% to $99000.0 in 2023, then soared by 324.24% to $420000.0 in 2024, then soared by 254171.67% to $1.1 billion in 2025, then slumped by 155.75% to -$595.4 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$595.4 million, $1.1 billion, and $1.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Edgewise Therapeutics | 4.76 Bn | 4.76 Bn | - | 1.10 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.10 Bn |
| Mar 31, 2026 | -595.40 Mn |
| Dec 31, 2025 | 1.07 Bn |
| Sep 30, 2025 | 1.05 Bn |
| Jun 30, 2025 | -455.50 Mn |
| Mar 31, 2025 | 848.68 Mn |
| Dec 31, 2024 | 420,000.00 |
| Sep 30, 2024 | -338.91 Mn |
| Jun 30, 2024 | -1.05 Mn |
| Mar 31, 2024 | -861,000.00 |
| Dec 31, 2023 | 99,000.00 |
| Sep 30, 2023 | 505.47 Mn |
| Jun 30, 2023 | -188.90 Mn |
| Mar 31, 2023 | -167.44 Mn |
| Dec 31, 2022 | -1.36 Mn |
| Sep 30, 2022 | -125.20 Mn |
| Jun 30, 2022 | -107.69 Mn |
| Mar 31, 2022 | 353.90 Mn |
| Dec 31, 2021 | -76.96 Mn |
| Sep 30, 2021 | -64.26 Mn |